GET DAILY SIGNALSAktis Oncology (AKTS): Analyst Targets Signal +125% Upside Potential
Key Takeaways
- The central target of $36 represents the arithmetic mean of eight verified analyst price targets for AKTS, rounded for simplicity, with the underlying average coming in near $35.6.
- Individual targets range from roughly $31 to $40, highlighting meaningful differences in views on how fast the radiopharmaceutical pipeline can deliver value.
- Trading near $16, the stock would need to climb about 125% to reach $36, which would be a substantial move under any measure.
- Key supports include a consensus leaning toward Strong Buy, cash runway expected to last into 2029, and an up-to-$1.1 billion research collaboration with Eli Lilly.
- Major risks center on early-stage clinical work, binary trial outcomes, and reliance on collaboration revenue plus future financing.
- For additional context, check the ticker’s Major News, Today's Price Move, Forecast, and Earnings pages for the latest updates.
- Explore Trending AI Robots for automated strategies that track shifting market conditions across thousands of stocks and ETFs.
Analyst Price Targets and Consensus View
Eight verified, individually attributed analyst targets were examined. They span from $31 (Leerink Partners, Outperform) to $40 (Oppenheimer, Outperform, and Raymond James, Strong Buy). Additional contributors include Bank of America ($34, Buy), BMO Capital ($37, Outperform), JPMorgan ($33, Overweight), H.C. Wainwright ($35, Buy), and Wedbush ($35, Outperform). The arithmetic mean of these eight targets sits near $35.6, which rounds to the central target of $36. Independent consensus sources paint a comparable picture, with averages around $35.4 to $35.9 across 9 to 10 analysts.
This group is uniformly bullish, with no Hold or Sell ratings appearing in the set. JPMorgan lifted its target from $30 to $33, while H.C. Wainwright’s Robert Burns raised his from $33 to $35. The optimism centers on Aktis’ miniprotein-enabled radioligand therapy platform, which analysts see as offering improved tumor targeting and safety compared with earlier approaches, along with pipeline flexibility. The wide $31-to-$40 spread nevertheless shows differing opinions on the value of assets that remain largely in early clinical testing. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
Aktis Oncology, Inc. (AKTS) is a clinical-stage oncology company focused on targeted radiopharmaceuticals for solid tumors. It completed its IPO on January 9, 2026, at $18 per share. The stock has recently traded near $16, within a 52-week range of roughly $14.72 to $34.19, giving it a market capitalization around $900 million to $1 billion. Reaching the $36 central target from about $16 would require upside of roughly 125%, which must be viewed as a very large move.
The path is not a valuation-expansion story but a clinical-development story. Aktis reported about $6.5 million in 2025 revenue, primarily collaboration income, against a net loss of roughly $63.7 million. It does not yet have an approved product, so any sustained move toward $36 likely depends on positive data readouts, advancing its lead programs such as AKY-1189 and AKY-2519, and continued analyst support as milestones are met.
What Could Support a Move Toward the Target
- Cash runway: The company has reported a pro forma cash position of more than $500 million, which management and analysts estimate can fund operations into 2029, reducing near-term dilution risk.
- Eli Lilly partnership: A research collaboration announced in early 2024 is worth up to $1.1 billion and validates the radiopharmaceutical platform.
- Clinical progress: The FDA cleared the IND application for AKY-2519, with a Phase 1b trial planned for 2026, and the company presented favorable imaging and dosimetry data at the 2026 ASCO meeting.
- Analyst conviction: A consensus of Buy and Strong Buy ratings, with several targets raised, supports sentiment if execution continues.
What Could Prevent the Target From Being Reached
- Binary clinical risk: Radiopharmaceutical programs can fail at any trial stage; a disappointing readout could reset the entire valuation.
- No approved products: Revenue is essentially collaboration income, so there is no commercial base to cushion a setback.
- Competition: The targeted radiopharmaceutical space is crowded, with larger, better-funded players advancing competing assets.
- Financing dependence: While the runway is long, future capital needs or dilution could pressure the share price.
- Valuation and volatility: As a pre-revenue biotech, AKTS trades on narrative and data, making it prone to sharp drawdowns.
Technical Levels and Market Structure
The chart reflects a newly public, volatile stock. The 52-week low near $14.72 serves as a key support level, with the $18 IPO price acting as a nearby reference and $20 as a psychological round-number level. On the upside, $30 and the prior high near $34.19 represent resistance levels the stock would need to clear on any sustained move toward $36. From what I see, these levels help frame the technical landscape as the company advances its pipeline.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, and the targets used here appear consistent with that convention, though firms may differ. Investors should watch quarterly earnings and cash-burn updates, the initiation of the AKY-2519 Phase 1b trial, any data readouts for AKY-1189, regulatory milestones, and analyst target revisions, which tend to move this type of stock quickly. I’m watching this closely as new clinical updates emerge.
Final Assessment
Can AKTS reach $36? The target is a fair representation of a bullish analyst base whose individual views range from $31 to $40. It implies a very large gain of roughly 125% from current levels and depends almost entirely on clinical execution rather than near-term financials. Strong cash reserves, a marquee partnership, and analyst conviction provide support, but binary trial outcomes, competition, and the absence of commercial revenue are serious obstacles. The question is ultimately less about valuation and more about whether Aktis’ radiopharmaceutical data will continue to justify analyst optimism.
Using Tickeron’s AI Daily Buy/Sell Signals in Research
In my own work, I turn to Tickeron’s AI Daily Buy/Sell Signals to monitor names like this one. The tool applies artificial intelligence to track thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions and technical behavior. For a volatile, news-sensitive stock such as AKTS, it offers an efficient way to spot opportunities and track trends alongside traditional analysis, helping keep research grounded in real-time data.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for AKTS turns positive, indicating new upward trend
AKTS saw its Momentum Indicator move above the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 65 similar instances where the indicator turned positive. In 58 of the 65 cases, the stock moved higher in the following days. The odds of a move higher are at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AKTS's RSI Indicator exited the oversold zone, 25 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for AKTS just turned positive on October 21, 2026. Looking at past instances where AKTS's MACD turned positive, the stock continued to rise in 25 of 31 cases over the following month. The odds of a continued upward trend are 81%.
Following a +10.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where AKTS advanced for three days, in 172 of 204 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
AKTS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The 50-day moving average for AKTS moved below the 200-day moving average on October 27, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AKTS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for AKTS entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 14 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.815) is normal, around the industry mean (3.498). P/E Ratio (-11.965) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (125.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. AKTS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 67 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AKTS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of filter products for radio frequency front-ends for mobile wireless devices
Industry Biotechnology
Advertisement